Both Forth Bridges

St. Louis Clinical Trials

St. Louis, MO

St. Louis Clinical Trials Overview

Principal Investigator
Daniel Gruener, M.D.,
Medical Director
Chief Medical Officer for Evolution Research Group

Sub-Investigators
Oksana Baram, M.D.
William Haynes, PsyD
Mary Quigley

Senior Director, Clinical Operations and Site Development
Erica Ridolfi

Specialties

Post-Op Pain
Bunion
Hernia
Addiction
ADHD
Alzheimer’s Disease
Bipolar Disorder
CLBP
CRPS
Depression
Diabetes
Diabetic Neuropathy
Essential Tremor
Hepatitis
Movement Disorders
Opioid Use Disorder
Osteoarthritis
Pain (Acute/Chronic)
PTSD
Schizophrenia
Sleep Disorders
Smoking/Tobacco

Facility

  • St. Louis Clinical Trials is a 24-bed, purpose-built facility with the capabilities to conduct specialized and complex study designs.
  • The facility maintains a compounding pharmacy with a Laminar flow hood; a double-locked, limited access drug storage room with a 24-hour monitoring system; an IATA and CLIA certified processing laboratory; and -20 degree and -70 degree sample storage.
  • Indoor smoking room equipped with a recirculating ventilation system.
  • Dedicated, controlled and secure outdoor smoking area.
  • Experience with topography, spirometry, CO measurements and PK biomarkers.
  • On-site long-term storage.
  • Research staff is proficient in all standard rating scales.
  • Full-time recruitment team for identifying quality research subjects throughout Greater St. Louis.

Special Procedures and Equipment
CSF/cCSF
Polysomnography
Smoking Room
EEG/qEEG
Crash Cart

Off-Site
MRI/fMRI
PET
X-ray
Ultrasound
DaT Scan
CT Scan

Institutional Review Board
Central

Follow Us On Social Media:
Facebook
Twitter

Contact
info@cnssites.com
+1-908-756-4411

Social Media

Unable to display Facebook posts.
Show error

Error: (#4) Application request limit reached
Type: OAuthException
Code: 4
Please refer to our Error Message Reference.

News Feed

March 19, 2018:

St. Louis Clinical Trials Participates in Bringing New Non-Opioid Pain Control Medicine to the Market

SLCT was one of the sites that participated in hernia repair studies, investigating a non-opioid postoperative pain medicine. The sponsor, Heron Therapeutics, has announced positive topline results from its completed Phase 3 studies of the investigational agent HTX-011 in subjects undergoing bunionectomy and hernia repair, which achieved all primary and key secondary endpoints in both Phase 3 trials, demonstrating statistically significant reductions in both pain intensity and the use of opioid rescue medications through 72 hours following surgery.

CLICK HERE to read about the positive topline results from the Phase 3 clinical trial.

May, 2017: The site welcomes Sean Faggioli, Early Phase Services Project Lead. Sean comes to us with six years of early phase experience, with five years of experience managing the set up and conduct of human abuse liability trials. Sean will partner with Dr. Daniel Gruener, Medical Director, to expand our capabilities in pain management, addiction and HAL. Over the past year, SCLT has expanded its capabilities from psychiatry and other CNS indications to include studies in CRPS, OA, CLBP, chronic pain, PTSD and essential tremors. Additions to our team include two experienced CRCs, and a F/T Pharmacist and QA Director. In 2016, the team established a relationship with Washington University, a premier radiological center, providing a full range of services and ability to expand our imaging capabilities. This alliance allows our site to have access to state-of-the-art imaging facilities, and has expanded our abilities to include studies requiring fMRI. To foster relationships within its community, SLCT joined the St. Louis Chapter of the Alzheimer’s Association and participated in the 2016 Alzheimer’s Walk. This year the staff will participate in NAMI walks to increase awareness and raise funds for mental illness.